Citigroup’s Pacira BioSciences PCRX Stock Holding History

Citigroup’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-200	Closed	-$7K	–	7641
2020 Q1	$7K	Sell	200 -3,800	-95%	-$158K	﹤0.01%	7178
2019 Q4	$181K	Sell	4,000 -1,200	-23%	-$51K	﹤0.01%	5265
2019 Q3	$198K	Buy	5,200 +3,000	+136%	+$120K	﹤0.01%	5153
2019 Q2	$96K	Buy	2,200 +1,200	+120%	+$50.9K	﹤0.01%	5916
2019 Q1	$38K	Buy	+1,000	New	+$39K	﹤0.01%	6562
2018 Q4	–	Sell	-5,700	Closed	-$280K	–	7793
2018 Q3	$280K	Sell	5,700 -5,900	-51%	-$255K	﹤0.01%	4902
2018 Q2	$372K	Sell	11,600 -400	-3%	-$13.8K	﹤0.01%	4405
2018 Q1	$374K	Buy	12,000 +4,900	+69%	+$174K	﹤0.01%	4292
2017 Q4	$324K	Buy	7,100 +4,400	+163%	+$174K	﹤0.01%	4561
2017 Q3	$101K	Sell	2,700 -800	-23%	-$32.2K	﹤0.01%	5565
2017 Q2	$167K	Buy	3,500 +1,900	+119%	+$88.2K	﹤0.01%	4942
2017 Q1	$73K	Sell	1,600 -900	-36%	-$38.9K	﹤0.01%	5444
2016 Q4	$81K	Sell	2,500 -1,000	-29%	-$33.4K	﹤0.01%	5896
2016 Q3	$120K	Buy	+3,500	New	+$137K	﹤0.01%	5076

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's PCRX Position: Q1 2026 in Review

Citigroup reduced its Pacira BioSciences (PCRX) stake by 17% in Q1 2026, selling an estimated $129K and leaving 29,117 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Citigroup first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.62M in Q2 2017. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Citigroup held 29,117 shares of Pacira BioSciences worth $658K as of Q1 2026.
Citigroup sold 5,825 Pacira BioSciences shares in Q1 2026, an estimated $129K.
Pacira BioSciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3383 holding.
Citigroup first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
Citigroup's Pacira BioSciences position peaked at $4.62M in Q2 2017.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.